Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRXFree Report) in a research report report published on Monday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Down 1.3 %

Shares of EGRX opened at $4.61 on Monday. Eagle Pharmaceuticals has a 52-week low of $3.95 and a 52-week high of $23.52. The company has a 50-day simple moving average of $4.94 and a 200-day simple moving average of $6.07. The company has a market capitalization of $59.88 million, a PE ratio of 3.91 and a beta of 0.46.

Institutional Investors Weigh In On Eagle Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of EGRX. Headlands Technologies LLC increased its stake in Eagle Pharmaceuticals by 75.7% in the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 2,861 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Eagle Pharmaceuticals by 623.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock valued at $36,000 after purchasing an additional 5,896 shares during the last quarter. DGS Capital Management LLC purchased a new position in shares of Eagle Pharmaceuticals in the fourth quarter valued at $60,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Eagle Pharmaceuticals during the 1st quarter worth $83,000. Finally, Aristides Capital LLC purchased a new stake in shares of Eagle Pharmaceuticals in the 4th quarter worth about $86,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

(Get Free Report)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Further Reading

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.